The Motley Fool
12 Jul 2026, 21:38 UTC · 2h ago
An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

The Motley Fool
12 Jul 2026, 21:38 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What the story claims
4 claims · each scored for market impact
Adaptive Biotechnologies raised its full-year MRD guidance to between $260 million and $270 million. — Upward revisions in revenue guidance typically signal strong organic growth and boost investor confidence in the company's trajectory.
+0.60The company's first-quarter revenue increased by 35% to $70.9 million, with clonoSEQ test volume rising 41%. — Strong top-line growth and volume increases in a core diagnostic product demonstrate market adoption and scalability.
+0.50Adaptive Biotechnologies' net loss narrowed to $20 million in the first quarter from a trailing twelve-month loss of $49.7 million. — A narrowing net loss suggests the company is moving closer to profitability, reducing the long-term risk for shareholders.
+0.40Continue reading
6 related stories
Top 2 movers · tap to explore
Chief Scientific Officer Harlan Robins sold 386,240 shares at $22.01 per share under a preset trading plan. — While insider selling can be a negative signal, this was a pre-scheduled sale and the insider retained a significant position, limiting the impact.
-0.20Which stocks this story touches
The company shows strong revenue growth, narrowing losses, and raised guidance, which outweighs the impact of an insider's pre-planned stock sale.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story

The Motley Fool
5h ago